Tumor necrosis factor antagonists for the treatment of neurologi

Details Tumor necrosis factor antagonists for the treatment of neurologi Tumor necrosis factor antagonists for the treatment of neurologi

1999-03-23

2000-01-18

Jarvis, William R. A.

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

514249, 514378, A61K 39395, A61K 31495, A61K 3150, A61K 3142

Patent

active

060155574

ABSTRACT:
A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing damage to neuronal tissue or for modulating the immune response affecting neuronal tissue of the human. The TNF antagonist administered is selected from the group consisting of etanercept and infliximab. The TNF antagonist is administered subcutaneously, intravenously, intrathecally, or intramuscularly.
Methotrexate or Leflunomide may be administered concurrently with the TNF antagonist for demyelinating diseases and certain other neurological disorders.

REFERENCES:
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5795967 (1998-08-01), Aggarwal et al.

Affiliated with

Also associated with

Rating

Tumor necrosis factor antagonists for the treatment of neurologi does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor necrosis factor antagonists for the treatment of neurologi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor necrosis factor antagonists for the treatment of neurologi will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-561155